|
Music Aids Patient Recovery from Surgery - Renal and Urology News |
August 17, 2015
Patients who listened to music had less pain, anxiety, and analgesia use after their operations, compared with patients receiving routine care or non-drug interventions.
Music can soothe the soul and the body. A new systematic review and meta-analysis confirms that listening to music improves patient recovery after surgical procedures.
Catherine Meads, PhD, of Brunei University in Uxbridge, UK, and colleagues analyzed 73 randomized controlled trials in which patients heard music before, during, or after surgery (with or without sedation or anesthesia). Unlike previous reviews, the researchers considered more than one aspect of the patient experience and all types of elective surgery from minor procedures to transplantation (with the exception of operations of the head, neck, or central nervous system). They also investigated the timing of music, choice of music, and the pairing of music and anesthesia. In the individual studies, music was compared to routine care, no music, white noise, or undisturbed bed rest.
The meta-analysis revealed that music decreased post-operative pain, anxiety, and use of pain medications, while increasing patient satisfaction, according to results published in The Lancet. It did not, however, affect length of hospital stay. The choice and timing of music made little difference, although most often it was soothing. Music even helped patients under general anesthesia (although the effects were larger when patients were awake).
“Modern theories of pain suggest that pain experience is affected by physical and psychological factors. Cognitive activities such as listening to music can affect perceived intensity and unpleasantness of pain, enabling patients' sensation of pain to be reduced,” the investigators explained. “Another potential mechanism could be reduced autonomic nervous system activity, such as reduced pulse and respiration rate and decreased blood pressure.”
Care needs to be taken to ensure music does not disturb the team performing the operation, the researchers stated. In most of the studies, the music volume was low enough that patients could hear instructions and respond to questions. It was delivered via headphones or music pillows directly to the patient or by a speaker that all could hear.
The investigators believe that enough evidence supports music that it should be made available to surgery patients with the conditions adapted to the clinical setting.
Source
- Hole, J; Hirsch, M; Ball, E; and Meads, C. The Lancet; doi: 10.1016/S0140-6736(15)60169-6.
|
|
|
Company Shares of NxStage Medical, Inc. (NASDAQ:NXTM) Rally 1.56% - American Trade Journal |
|
Shares of NxStage Medical, Inc. (NASDAQ:NXTM) rose by 1.56% in the past week and 28.57% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.88% and the outperformance increases to 30.73% for the last 4 weeks.
The company shares have rallied 37.93% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $14.92 and the 200 day moving average is recorded at $16.69. S&P 500 has rallied 6.56% during the last 52-weeks. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares have been rated as hold from 1 Wall Street Analysts. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Nxstage Medical, Inc. is up 9.27% in the last 3-month period. Year-to-Date the stock performance stands at 1.9%. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $18.14 and hit $18.4099 on the upside , eventually ending the session at $18.27, with a gain of 0.27% or 0.05 points. The heightened volatility saw the trading volume jump to 335,709 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $1,159 million. The 52-week low of the share price is at $11.5 . Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -6.42% in the total insider ownership. Institutional Investors own 94.4% of Company shares. During last 3 month period, -1.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|
Serum Chloride Levels Linked to Mortality in Heart Failure Patients - Renal and Urology News |
August 17, 2015
Independent and inverse correlation seen for mortality with acute decompensated heart failure.
(HealthDay News) -- Serum chloride levels at admission are associated with mortality among patients with acute decompensated heart failure (ADHF), according to a study published in the Journal of the American College of Cardiology.
Justin L. Grodin, M.D., from the Cleveland Clinic, and colleagues examined the prognostic significant of sodium chloride levels in relation to serum sodium levels in a cohort of 1,318 patients with chronic heart failure admitted for ADHF. Findings were validated in an independent cohort of 876 ADHF patients.
The researchers observed an independent and inverse association for admission serum chloride levels during hospitalization for ADHF and long-term mortality (hazard ratio [HR] per unit change, 0.94; P < 0.001). After multivariable risk adjustment, admission chloride levels, but not sodium levels, remained independently associated with mortality (HR per unit change, 0.93; P < 0.001 and P > 0.05, respectively). Similar results were seen in the validation cohort in unadjusted and multivariable risk-adjusted analyses (HRs per unit change for mortality risk within one year, 0.93 [P < 0.001] and 0.95 [P = 0.01], respectively).
"These observations in a contemporary advanced ADHF cohort suggest that serum chloride levels at admission are independently and inversely associated with mortality," the authors write. "The prognostic value of serum sodium in ADHF was diminished compared with chloride."
Sources
- Grodin, JL; Simon, J; Hachamovitch, R; et al. J Am Coll Cardiol. 2015;66(6):659-666; doi:10.1016/j.jacc.2015.06.007.
- O'Connor, CM and Ahmad, T. J Am Coll Cardiol.2015;66(6):667-669; doi:10.1016/j.jacc.2015.05.070.
|
|
Lipocalin-2 may be a biomarker for renal disease activity in patients with ... - Healio |
|
Urinary lipocalin-2 levels may be a useful biomarker for detecting renal disease activity in patients with lupus nephritis, according to the results of a study.
Researchers studied 50 adult patients with systemic lupus erythematosus (SLE) who met 1997 American College of Rheumatology (ACR) criteria and 20 matched healthy participants.
All participants underwent clinical and serological evaluation. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were calculated for patients with SLE. Urinary lipocalin-2 was measured in all participants.
Patients with SLE had significantly higher levels of urinary lipocalin-2 compared to healthy participants (13.2 /mL vs. 1.7 /mL), and patients with lupus nephritis had significantly higher levels of lipocalin-2 than all participants (22.95 /mL). Renal SLEDAI scores correlated positively with increased levels of lipocalin-2, but the levels did not correlate with other symptoms of disease unrelated to renal involvement.
Of 25 patients with 1-year follow-up data available, a significant difference was seen in urinary lipocalin-2 levels between patients with and without lupus nephritis. An association between the change in the total and renal SLEDAI scores and urinary lipocalin-2 levels was noted but it did not reach statistical significance.
The authors concluded that the levels of urinary lipocalin-2 may be useful in predicting renal disease activity in patients with SLE. – by Shirley Pulawski
Reference:
Gamal NM, et al. Paper #SAT0413. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology. June 10-13, 2015; Rome.
Disclosure: The researchers report no relevant financial disclosures.
|
|
Company Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) Drops by -9.45% - Insider Trading Report |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 9.45% during the past week and dropped 29.76% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 10.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 28.58% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
The company shares have rallied 12.7% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.63 and the 200 day moving average is recorded at $12.13. S&P 500 has rallied 6.56% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Rockwell Medical, Inc. is up 26.12% in the last 3-month period. Year-to-Date the stock performance stands at 23.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Friday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $11.53 and hit $12.79 on the upside , eventually ending the session at $12.65, with a gain of 9.62% or 1.11 points. The heightened volatility saw the trading volume jump to 1,234,072 shares. The 52-week high of the share price is $18.8999 and the company has a market cap of $635 million. The 52-week low of the share price is at $8.095 .
Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0.73% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at $11.96 per share with total amount equaling $58,724. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
